Affordable Access

Publisher Website

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

  • Tuttle, Katherine R1, 2, 3
  • Brosius, Frank C 3rd4, 5
  • Adler, Sharon G6
  • Kretzler, Matthias4
  • Mehta, Ravindra L7
  • Tumlin, James A8
  • Tanaka, Yoshiya9
  • Haneda, Masakazu10
  • Liu, Jiajun11
  • Silk, Maria E11
  • Cardillo, Tracy E11
  • Duffin, Kevin L11
  • Haas, Joseph V11
  • Macias, William L11
  • Nunes, Fabio P11
  • Janes, Jonathan M11
  • 1 Providence Health Care, Spokane, WA, USA.
  • 2 The Kidney Research Institute, Division of Nephrology, University of Washington School of Medicine, Seattle, WA, USA.
  • 3 The Institute of Translational Health Sciences, University of Washington School of Medicine, Seattle, WA, USA.
  • 4 Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 5 Department of Internal Medicine, University of Arizona College of Medicine, Tucson, AZ, USA.
  • 6 Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
  • 7 Division of Nephrology, University of California, San Diego, CA, USA.
  • 8 University of Tennessee College of Medicine, Chattanooga, TN, USA.
  • 9 The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. , (Japan)
  • 10 Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan. , (Japan)
  • 11 Eli Lilly and Company, Indianapolis, IN, USA. , (India)
Published Article
Nephrology Dialysis Transplantation
Oxford University Press
Publication Date
Feb 22, 2018
DOI: 10.1093/ndt/gfx377
PMID: 29481660


Baricitinib decreased albuminuria in participants with Type 2 diabetes and DKD. Further research is required to determine if baricitinib reduces DKD progression.

Report this publication


Seen <100 times